1. Others
  2. Others
  3. P7C3

P7C3 

Cat. No.: HY-15976 Purity: 99.97%
Handling Instructions

P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease.

For research use only. We do not sell to patients.

P7C3 Chemical Structure

P7C3 Chemical Structure

CAS No. : 301353-96-8

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 66 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 60 In-stock
Estimated Time of Arrival: December 31
10 mg USD 96 In-stock
Estimated Time of Arrival: December 31
50 mg USD 384 In-stock
Estimated Time of Arrival: December 31
100 mg USD 696 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of P7C3:

Top Publications Citing Use of Products

    P7C3 purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2018 Jan 1;11(1):293-303.

    Expression of Nampt, RelB, Bax, PARP-1 is detected by western blot and hippocampal primary neuronal apoptosis by Flow cytometry. Nampt and RelB protein are up-regulated, and Bax, PARP-1 proteins are down-regulated by P7C3 stimulation in advance compared with Sev-N2O group.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease[1][2][3].

    In Vitro

    P7C3 inhibits LPS-induced production of pro-inflammatory factors in BV2 cells[3].
    P7C3 markedly reduces the protein levels of iNOS and COX-2 in a dose-dependent manner without affecting the cell viability in the LPS (100 ng/mL)-stimulated BV2 cells[3].
    P7C3 inhibits LPS-induced nuclear translocation of NF-κB p65 subunit in BV2 cells[3].
    P7C3 suppresses LPS-induced degradation of inhibitory κB alpha (IκBα) by inhibiting IκB kinase (IKK) activation[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[3]

    Cell Line: BV2 cells
    Concentration: 0.1 μM, 1 μM, 10 μM
    Incubation Time: 2 hours
    Result: Reduced the protein levels of iNOS, COX-2.
    In Vivo

    P7C3 (20 mg/kg/d; i.p.; twice daily; for 21 days ) inhibits microglial activation and microglia-mediated dopaminergic (DA) neuronal loss in vivo[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 6-8 weeks male C57BL/6 mice (25-30 g)[3]
    Dosage: 20 mg/kg/d
    Administration: Intraperitoneal injection, twice daily, for 21 days
    Result: Strikingly decreased the expressions of (a microglia marker) and GFAP (an astrocyte marker) LPS-induced in the substantia nigra pars compacta (SNpc).
    Molecular Weight

    474.19

    Formula

    C₂₁H₁₈Br₂N₂O

    CAS No.
    SMILES

    OC(CNC1=CC=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 33 mg/mL (69.59 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1089 mL 10.5443 mL 21.0886 mL
    5 mM 0.4218 mL 2.1089 mL 4.2177 mL
    10 mM 0.2109 mL 1.0544 mL 2.1089 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 99.97%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    P7C3Othersneuroprotectiveneurodegenerationneurodegenerative diseasesnervecellinjuryParkinson'sdiseaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    P7C3
    Cat. No.:
    HY-15976
    Quantity:
    MCE Japan Authorized Agent: